



Announcement Summary

Entity name

PACIFIC EDGE LIMITED

Announcement Type

New announcement

Date of this announcement

17/7/2025

The Proposed issue is:

A placement or other type of issue

Total number of +securities proposed to be issued for a placement or other type of issue

ASX +security code	+Security description	Maximum Number of +securities to be issued
PEB	ORDINARY FULLY PAID FOREIGN EXEMPT NZX	160,728,498

Proposed +issue date

13/8/2025

Refer to next page for full details of the announcement

Part 1 - Entity and announcement details

1.1 Name of +Entity

PACIFIC EDGE LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type

ARBN

Registration Number

653308144

1.3 ASX issuer code

PEB

1.4 The announcement is

New announcement

1.5 Date of this announcement

17/7/2025

1.6 The Proposed issue is:

A placement or other type of issue



Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?

Yes

7A.1a Conditions

Approval/Condition	Date for determination	Is the date estimated or actual?	** Approval received/condition met?
+Security holder approval	6/8/2025	Actual	

Comments

At the Annual Shareholders Meeting on 6 August 2025, Shareholders are being asked to approve a placement of 160,728,498 new fully paid ordinary shares in Pacific Edge to investors selected by Pacific Edge, including to certain related party participants, at an issue price of NZD 0.10 per Share.

The Placement was completed on 30 May 2025 with applications for NZD16,072,850 of new Shares accepted by Pacific Edge, with allotment under the Placement conditional on shareholder approval and regulatory relief. The regulatory relief condition to the Placement was satisfied on 12 June 2025 when Pacific Edge obtained a waiver from Listing Rule 4.19.1 to permit it to allot Shares under the Placement following the Meeting.

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?
Existing class

Will the proposed issue of this +security include an offer of attaching +securities?
No

Details of +securities proposed to be issued

ASX +security code and description

PEB : ORDINARY FULLY PAID FOREIGN EXEMPT NZX

Number of +securities proposed to be issued

160,728,498

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?
Yes

In what currency is the cash**What is the issue price per**

**consideration being paid?**

NZD - New Zealand Dollar

+security?

NZD 0.10000

AUD equivalent to issue price amount per +security

0.091000

FX rate (in format AUD 1.00 / primary currency rate):

AUD 1.00

FX rate (in format AUD rate/primary currency rate) Primary Currency rate

NZD 1.09500000

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

Part 7C - Timetable**7C.1 Proposed +issue date**

13/8/2025

Part 7D - Listing Rule requirements**7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?**

No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?

No

Part 7E - Fees and expenses**7E.1 Will there be a lead manager or broker to the proposed issue?**

No

7E.2 Is the proposed issue to be underwritten?

No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

Standard legal, registry costs and corporate advisory fees to Cameron Partners in line with customary levels for transactions of this nature.

Part 7F - Further Information**7F.01 The purpose(s) for which the entity is issuing the securities**

Raise capital to ensure the company has the resources and capacity to capitalise on its recent clinical and commercial milestones, grow into non-Medicare channels and regain Medicare coverage.



7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?

No

7F.2 Any other information the entity wishes to provide about the proposed issue

7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

An applicable ASIC instrument or class order